Q-omics provides the consensus-scored SGCZ profile across patient tissues and cancer cell-line models. SGCZ expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SGCZ is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SGCZ RNA expression shows 11,489 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where SGCZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SGCZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SGCZ survival associations across molecular data types. SGCZ RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SGCZ RNA expression–survival associations across cancer types. High SGCZ expression shows unfavorable associations in KIRC, ACC, STAD, KIRP, LUAD and PCPG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SGCZ RNA expression.
This table summarizes SGCZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SGCZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SGCZ shows lower tumor expression in KIRC, KICH, BRCA and UCEC and higher tumor expression in HNSC and LUSC. The KIRC box plot shows higher SGCZ RNA expression in normal versus tumor tissue (log2 FC = −0.585, t-test p < 0.001).
This table shows molecular features associated with SGCZ in patient tissues and cancer cell lines. In patient samples, SGCZ shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SGCZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
